Compare Home Depot Inc (HD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Pfizer Inc — how do they compare? Home Depot Inc trades at $354.99 (market cap $349.77B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Home Depot Inc is far larger — about 2.3× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| HD | PFE | |
|---|---|---|
Market Cap | $349.77B | $154.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $28.56 |
52-Week Low | $297.51 | $23.60 |
Enterprise Value | $411.32B | $205.67B |
Dividend Yield | 2.66% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $354.48, down 0.32% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $368.75. The stock shows strong profitability with a net margin of 8.41% and ROE of 128.38%, though recent earnings have been mixed with a Q3 2025 miss but Q4 2025 and Q1 2026 beats. Revenue grew to $159.51 billion in 2025, while cash flow from operations remains robust at $19.81 billion, supporting a recent dividend of $2.33 per share.
The outlook is supported by analyst optimism (59% buy ratings) and Pro business growth, but risks include weakening big-ticket demand, margin pressures from investments, and sensitivity to housing market trends. The stock's valuation at a P/E of 24.91 may limit near-term upside if earnings growth slows.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
